AIM Vaccine Co., Ltd. (6660.HK)

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People's Republic of China and internationally. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine. In addition, the company develops 20-valent and 24-valent pneumonia conjugate vaccine, haemophilus influenzae type b conjugate vaccine, absorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells), and human diploid rabies vaccine. Further, it offers hexavalent meningococcal vaccine to treat meningococcal disease; hexavalent group b streptococcus polysaccharide conjugate vaccine; mRNA human rabies vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; diphtheria, tetanus, pertussis and haemophilus influenzae type b, and acellular pertussis combination vaccine for the treatment of DTP; and recombinant group B meningococcal vaccine to treat meningococcal disease. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. The company was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.